Cumberland Pharmaceuticals Inc. CPIX
5.36 USD -0.01 (-0.28%)
Nov 10, 2026, 11:39 AM EST
5.33 Day range 5.54
1.85 52-week range 9.28
- YTD
- +34.55%
- 1 year
- +170.45%
Benzinga news
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Senti Biosciences (NASDAQ:SNTI) stock rose 51.8% to $0.27 during Monday's after-market session. The company's market cap stands at $5.9 million. Polyrizon (NASDAQ:PLRZ) shares increased by…
benzinga.com Cumberland Pharmaceuticals Intends To File New Drug Application To FDA For Ifetroban To Treat Cardiomyopathy Associated With Duchenne Muscular Dystrophy Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), ("Cumberland" or the "Company") an innovation-focused biopharmaceutical company developing new products for rare diseases, today provided an update on…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares…
benzinga.com Cumberland Pharmaceuticals Announces Data From Its Phase 2 ASSIST-SSc Study Of Oral Ifetroban For Patients With Systemic Sclerosis; Gastrointestinal Adverse Events Were More Frequent In Ifetroban Group Than Placebo; Majority Of Patients Demonstrated Limited Disease Progression, Which Reduced Ability To Track Treatment Difference Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announces top-line results from…- benzinga.com Cumberland Q2 Adj. EPS $(0.20) Down From $(0.13) YoY, Sales $166.458K Down From $380.797K YoY Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.20) per share. This is a 53.85 percent decrease over losses of $(0.13) per share from the same period last year. The company reported…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 million. Supernus…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market session. The company's market cap stands at $66.4 million. ProMIS Neurosciences (NASDAQ:PMN) shares…
benzinga.com Cumberland Pharmaceuticals Declares $1.50/Share Special Dividend Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized…
benzinga.com Cumberland Pharma Advances Duchenne Program With New Safety, Efficacy Data Cumberland Pharma shares rose after Phase 2 data showed ifetroban improved heart function in Duchenne muscular dystrophy patients.
benzinga.com Redhill Biopharma Announces FDA Rare Pediatric Disease Designation For Opaganib For The Treatment Of Neuroblastoma The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young…
benzinga.com U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Cumberland And Vanderbilt Announce Phase 2a Clinical Trial Of Ifetroban Met Primary Endpoint Demonstrating Safety And Tolerability Of Ifetroban In Patients With High-Risk Solid Tumors Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising efficacy…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Why e.l.f. Beauty Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket Shares of elf Beauty Inc (NYSE: ELF) rose sharply in pre-market trading after beating analyst expectations with fourth-quarter earnings of 32 cents per share and revenue of $449.29 million, up 35%.…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Full Transcript: Cumberland Q1 2026 Earnings Call
benzinga.com Cumberland Q1 Adj. EPS $(0.13) Down From $0.16 YoY, Sales $9.131M Down From $11.713M YoY Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.13) per share. This is a 181.25 percent decrease over earnings of $0.16 per share from the same period last year. The company reported $9.131…
benzinga.com Earnings Scheduled For May 5, 2026 
benzinga.com Why Sterling Infrastructure Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket Shares of Sterling Infrastructure Inc (NASDAQ: STRL) jumped 22.5% in pre-market trading after reporting better-than-expected Q1 results and raising its FY26 guidance. Other gainers include BLZE,…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Crude Oil Gains Over 1%; US Initial Jobless Claims Edge Higher US stocks down, Nasdaq falls 0.4% on Thursday. Jobless claims rise to 214,000. Utilities jump 2.1%, ServiceNow shares drop 16%.
benzinga.com Dow Falls Over 200 Points; Tesla Shares Slip After Q1 Results Dow Jones drops 0.44%, NASDAQ falls 0.31%, S&P 500 down 0.22%. Tesla shares drop 1% after reporting earnings. Auddia Inc. and Cumberland Pharmaceuticals Inc. see significant gains.- benzinga.com Cumberland Pharmaceuticals Announces That Apotex Will Acquire The Company's Line Of Branded Pharmaceuticals For $100M In Cash Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a U.S. specialty pharmaceutical company, today announced it has entered into an agreement with an affiliate of Apotex ("Apotex"), the largest Canadian…
- benzinga.com Cumberland Q4 Adj. EPS $(0.01) Up From $(0.02) YoY, Sales $13.679M Up From $10.436M YoY Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.01) per share. This is a 50 percent increase over losses of $(0.02) per share from the same period last year. The company reported $13.679…
- benzinga.com Earnings Scheduled For March 3, 2026
benzinga.com FDA Grants Fast Track Designation For Cumberland Pharma's Oral Therapy Targeting Fatal Form Of Heart Disease In Duchenne Muscular Dystrophy Patients Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, announced today that the U.S. Food and Drug Administration…- benzinga.com Cumberland's Caldolor Injection Receives Permanent J-Code With Reimbursement Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), today announced an important update regarding its Caldolor® (ibuprofen) Injection. The product's permanent J-code, J1741, is now officially associated…
- benzinga.com Cumberland Q3 Adj. EPS $(0.06) Down From $(0.02) YoY, Sales $8.292M Down From $9.086M YoY Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.06) per share. This is a 200 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $8.292…
benzinga.com Earnings Scheduled For November 4, 2025 - benzinga.com Cumberland To Co-Commercialize Talicia With RedHill, For The Treatment Of Helicobacter Pylori Infection In Adults, A Bacterial Infection And Leading Risk Factor For Gastric Cancer Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapyNASHVILLE, Tenn., Oct. 20, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a…
- benzinga.com Cumberland Pharma Adds Potent Antibiotic, Vibativ, To National Group Purchasing Agreement With Premier Premier Membership includes 4,350 U.S. HospitalsNASHVILLE, Tenn., Oct. 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, has added their…
- benzinga.com Cumberland Pharmaceuticals' Ibuprofen Injection Receives Mexican Regulatory Approval To Treat Pain And Fever; PiSA To Roll Out Product In Mexico Injectable Ibuprofen Approved for Treating Pain & FeverNASHVILLE, Tenn., Oct. 1 , 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com CORRECTION: Cumberland Q2 Adj. EPS $0.02 Up From $0.01 YoY, Sales $10.838M Up From $9.849M YoY Cumberland (NASDAQ:CPIX) reported quarterly earnings of $0.02 per share. This is a 100 percent increase over earnings of $0.01 per share from the same period last year. The company reported $10.838…
- benzinga.com Earnings Scheduled For August 5, 2025
- benzinga.com Cumberland Pharma Announces Availability Of Vibativ 4-Vial Starter Pak Through New Contract With Vizient Vizient serves more than 65% of the nation's acute care providers, including 97% of academic medical centersNASHVILLE, Tenn., Aug. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.…
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Cumberland Pharma Presents Latest Results From Phase 2 FIGHT DMD Trial Evaluating Ifetroban, Oral Therapy For DMD Heart Disease, At PPMD Conference In Las Vegas New pharmacokinetic and cardiac biomarker data further demonstrate ifetroban's potential to protect the heart and reduce cardiac damage in DMD patientsNASHVILLE, Tenn., June 23, 2025 /PRNewswire/ --…
benzinga.com Cumberland Pharmaceuticals And Qureight Partner To Advance Idiopathic Pulmonary Fibrosis Treatment Research Cumberland leveraging Qureight's deep-learning AI platform for its Phase II FIGHTING FIBROSIS™ clinical trial- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Cumberland Q1 Adj. EPS $0.16 Up From $(0.05) YoY, Sales $11.71M Up From $8.50M YoY Cumberland (NASDAQ:CPIX) reported quarterly earnings of $0.16 per share. This is a 420 percent increase over losses of $(0.05) per share from the same period last year. The company reported $11.71…
- benzinga.com Earnings Scheduled For May 6, 2025
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Cumberland Q4 Adj EPS $(0.02) Up From $(0.11) YoY, Sales $10.44M Up From $9.35M YoY Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.02) per share. This is a 81.82 percent increase over losses of $(0.11) per share from the same period last year. The company reported $10.44…
- benzinga.com Earnings Scheduled For March 4, 2025
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
- benzinga.com Earnings Scheduled For March 5, 2024 Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.